Related to Oncobiologics Finds Partner to Launch Biosimilars in U.S., China

• Latest Guideline Summary Document Solidifies EMA as Front Runner in Biosimilar Regulation
  Agency sought to answer various procedural questions that could come up during presubmission meetings.
  
• FDA’s Hearing for Biosimilars Showcased Issues Ranging From Definitions to Study Requirements to IP
  Industry appeared to provide broad support for draft rules but pointed to areas that need tweaking.
  
• Russia Establishes Clinical Trial Hub
  Cost and speed play big roles in the country’s increased presence in the market.
  
• 10 Best U.S. Regions to Secure a Biotech Job
  GEN shows you where careers are made.
  
• DuBiotech: The Silicon Valley of Biotechnology
  The Dubai Biotechnology & Research Park is open for business and aiming to catch the eye of biotech companies.
  
• Biggest Biotech Trends of 2012
  GEN takes a look back at some key biopharma developments of the past 12 months.
  
• 7 Biotech Trends for the Coming Year
  What does 2013 hold for the industry?
  
• No Passage to India
  Private investment dearth clouds the future of the subcontinent’s fast-growing biopharma industry.
  
• Stockholm-Uppsala Region Ups the Ante
  The region bets big in the quest for international renown.
  
• Biosimilars: Not So Far So Fast
  Regulatory issues are among the hurdles that are slowing down biosimilar production.
  
• Electronics Giants Set Sights on Biotech
  Samsung, Sony eye life-sci’s higher growth as consumer electronics sales flatten.
  
• Bird Flu Back Again?
  H7N9 has killed six people so far. Find out what’s being done about it.
  
• Poland Invests in Biotech Infrastructure
  Will it be enough for the industry to succeed?
  
• Biosimilars: 10 Drugs to Watch
  Which innovator drugs are companies scrambling to copy?
  
• Requirements for China to Globalize Success Seen in Domestic Biosimilars Market
  Firms need to address manufacturing concerns and gain a better understanding of international regulatory activities.
  
• 2009 in Review: Headline-Making Stories in the Biotech Industry
  Even though last year was marred by the economic crash, the life science sector showed significant progress.
  
• Asia-Pacific’s March toward a New Drug Development Paradigm
  Increasing investment, embracing new R&D models, and aligning regulatory agencies are key to the region’s success.
  
• High-Tech Companies Buy Into Biomanufacturing
  Samsung and Fujifilm believe such high-investment diversification will help business.
  
• Asia’s Emerging Markets Catching Up to the U.S. and Europe in Terms of Innovation
  Countries like China and Korea are growing to be more than just manufacturing hubs.
  
• For Some Emerging Companies, the Road to Growth Connects the U.S. and China
  While American firms are tapping China’s size and regulatory path, Chinese biotechs are going west for money and expertise.